Baclofen for relieving pain from herpes zoster

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with herpes zoster who have had a rash for less than 90 days and report average pain of at least 4/10 are enrolled. Participants receive either baclofen in addition to conventional therapy or conventional therapy alone, with monitoring of liver and kidney function. The trial tracks pain intensity and adverse events to determine whether baclofen provides additional analgesia and is safe in this setting. Key exclusions include prior baclofen use, disseminated or ocular HZ, and known hypersensitivity to baclofen.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Ages more than 18 years;
* 2\. Patients with onset of HZ rash less than 90 days;
* 3\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);
* 4\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;
* 5\. Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher;
* 6\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.

Exclusion Criteria:

* 1\. History of taking baclofen;
* 2\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;
* 3\. History of intolerance or hypersensitivity to any active components or excipient of the baclofen;
* 4\. History of systemic immune diseases, organ transplantation, or cancers;
* 5\. Pregnancy or breastfeeding;
* 6\. Suffering from acute or chronic pain disorders other than HZ.

Where it's running

• Beijing Tiantan Hospital, Beijing, Beijing 100070
  Beijing, China Recruiting

Study contacts

• Study coordinator: Fang Luo
• Email: 13611326978@163.com
• Phone: 13611326978

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Recombinant Zoster Vaccine with ZFA01 Adjuvant in Adults 40+

  A two-part study tests a recombinant herpes zoster vaccine in healthy adults aged 40 and older to see if it boosts immune responses and is safe.

  Recruiting at 2 sites Phase 1/2 Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Guangxi, Nanning and 1 other locations · NCT07920172

• How long the live shingles vaccine protects you

  This will see if the live attenuated shingles vaccine keeps adults from the original Phase III trial protected against herpes zoster for up to six years after vaccination.

  Recruiting Jiangsu Province Centers for Disease Control and Prevention · Nanjing, Jiangsu · NCT07585370

• Recombinant zoster (Shingrix) to see if it lowers new dementia diagnoses in people 76 and older in Finland.

  This trial will test whether the Shingrix shingles vaccine lowers the chance of a new dementia diagnosis in people aged 76 or older who live in Finland.

  Recruiting at 8 sites Phase 4 GlaxoSmithKline · Espoo and 7 other locations · NCT07502560

• Erector spinae plane block versus transcutaneous radiofrequency for postherpetic neuralgia

  This project will see if erector spinae plane block or transcutaneous radiofrequency works better to reduce pain in adults with postherpetic neuralgia.

  Recruiting Diskapi Teaching and Research Hospital · Ankara · NCT07400640

• Lyophilized shingles mRNA vaccine safety and immune response

  This trial will test a lyophilized mRNA vaccine to see if it is safe and produces immune responses in adults aged 40 years and older.

  Recruiting Phase 1/2 Sinovac Biotech Co., Ltd · Xinjiang · NCT07400003

• Loxoprofen patch for relieving shingles pain

  This will test if adding a loxoprofen sodium patch to standard care reduces pain in adults with shingles.

  Recruiting Beijing Tiantan Hospital · Beijing · NCT07378059

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.